Yahoo Finance Insider Sale: Director Timothy Scannell Sells 7,000 Shares of Insulet Corp (PODD)
Director Timothy Scannell of Insulet Corp (NASDAQ:PODD) sold 7,000 shares of the company on June 10, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 35,586 shares of the company. The shares were sold at a price of $190.51, valuing the transaction at approximately $1,333,570.
Insulet Corp, headquartered in Massachusetts, is a medical device company primarily engaged in the development, manufacture, and sale of insulin infusion systems for people with insulin-dependent diabetes.
Over the past year, Timothy Scannell has sold a total of 10,300 shares of Insulet Corp and has not made any purchases of the stock. The insider transaction history for Insulet Corp shows a trend with 2 insider buys and 9 insider sells over the past year.
Shares of Insulet Corp were trading at $190.51 on the day of the transaction, giving the company a market cap of $13.46 billion. The price-earnings ratio of the company stands at 58.23, which is above the industry median of 28.52.
The stock's valuation metrics show a GF Value of $374.71, indicating that at the current price of $190.51, Insulet Corp is significantly undervalued with a price-to-GF-Value ratio of 0.51.
The GF Value is calculated considering historical trading multiples, an adjustment factor based on the company's past performance, and future business projections provided by Morningstar analysts.
This sale by the insider could be of interest to investors tracking insider behaviors and evaluating the stock's current valuation under the GF Value metric.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
